Effect of MCM09, an active site-directed inhibitor of factor Xa, on B16-BL6 melanoma lung colonies in mice

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 3, 2006, Pages 608-613

  Rossi, C ^a   Hess, S ^b,c   Eckl, R W ^b   Di Lena, A ^a   Bruno, A ^a   Thomas, O ^b   Poggi, Andreina ^a  

^a Consorzio Mario Negri Sud ^*  (Italy)

^b Biovertis AG   (Germany)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

APTT; B16 BL6 melanoma; Cancer; Factor Xa inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; MCM 09; SERINE PROTEINASE; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; FEMALE; INHIBITION KINETICS; LUNG METASTASIS; MELANOMA B16; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL;

ANIMALS; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BLOOD COAGULATION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FEMALE; HEPARIN; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PARTIAL THROMBOPLASTIN TIME; PIPERAZINES; PYRANS; TIME FACTORS;

EID: 33645999064     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01793.x     Document Type: Article

References (34)

1. Donati MB. Cancer and thrombosis: From Phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74: 278-81.
2. Donati MB, Semeraro N. Cancer cell procoagulants and their pharmacological modulation. Haemostasis 1984; 14: 422-9.
3. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102: V215-24.
4. Zacharski LR. Anticoagulants in cancer treatment: Malignancy as a solid phase coagulopathy. Cancer Lett 2002; 186: 1-9.
5. Loynes JT, Zacharski LR. The coagulation system as a target for experimental therapy of human gliomas. Expert Opin Ther Targets 2003; 7: 399-404.
6. Kakkar AK. An expanding role for antithrombotic therapy in cancer patients. Cancer Treat Rev 2003; 29: 23-6.
7. Tyrrell DJ, Kilfeather S, Page CP. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 1995; 16: 198-204.
8. Engelberg H. Actions of heparin that may affect the malignant process. Cancer 1999; 85: 257-72.
9. Parish CR, Coombe DR, Jakobsen KB, Bennett FA, Underwood PA. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour cell-derived heparanases. Int J Cancer 1987; 40: 511-8.
10. Poggi A, Rossi C, Casella N, Bruno C, Sturiale L, Dossi C, Naggi A. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide. Semin Thromb Hemost 2002; 28: 383-92.
11. Bobek V, Boubelik M, Kovarik J, Taltynov O. Inhibition of adhesion breast cancer cells by anticoagulant drugs and cimetidine. Neoplasma 2003; 50: 148-51.
12. Pross M, Lippert H, Misselwitz F, Nestler G, Kruger S, Langer H, Halangk W, Schulz HU. Low-molecular-weight heparin (reviparin) diminishes tumor cell adhesion and invasion in vitro, and decreases intraperitoneal growth of colonadeno-carcinoma cells in rats after laparoscopy. Thromb Res 2003; 110: 215-20.
13. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001; 98: 3352-7.
14. Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desal H, Francis JL. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002; 87: 930-6.
15. Lorenzet R, Donati MB. Blood clotting activation, angiogenesis and tumor metastasis: Any role for TFPI? Thromb Haemost 2002; 87: 928-9.
16. Rickles FR, Patierno SR, Fernandez PM. Targeting the endothelium in cancer -the importance of the interaction of hemostatic mechanisms and the vascular wall for tumor growth and angiogenesis. Pathophysiol Haemost Thromb 2003; 33: 1-4.
17. Kinder D, Elstad CA, Meadows GG, Ames MM. Antimetastatic activity of boro-amino acid analog protease inhibitors against B16BL6 melanoma in vivo. Invasion Metastasis 1992; 12: 309-19.
18. McLean K, Schirm S, Johns A, Morser J, Light DR. FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834. Thromb Res 2001; 103: 281-97.
19. Ilies MA, Scozzafava A, Supuran CT. Therapeutic applications of serine protease inhibitors. Expert Opin Ther Patents 2002; 12: 1181-214.
20. Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-84.
21. Hart IR. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 1979; 97: 587-600.
22. Cilenti L, Lee Y, Hess S, Srinivasula S, Park KM, Junqueira D, Davis H, Bonventre JV, Alnemri ES, Zervos AS. Characterization of a novel specific inhibitor for the pro-apoptotic protease Omi/HtrA2. J Biol Chem 2003; 278: 11489-94.
23. Amirkhosravi A, Mousa SA, Amaya M, Francis JL. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 2003; 1: 1972-6.
24. Senden NH, Jeunhomme TM, Heemskerk JW, Wagenvoord R, van't Veer C, Hemker HC, Buurman WA. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol 1998; 161: 4318-24.
25. Riewald M, Kravchenko VV, Petrovan RJ, O'Brien PJ, Brass LF, Ulevitch RJ, Ruf W. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. Blood 2001; 97: 3109-16.
26. Versteeg HH, Spek CA, Richel DJ, Peppelenbosh MP. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 2004; 23: 410-7.
27. Kragh M, Binderup L, Vig Hjarnaa PJ, Bramm E, Johansen KB, Frimundt Petersen C. Non-anticoagulant heparin inhibits metastasis but not primary tumor growth. Oncol Rep 2005; 14: 99-104.
28. Kirszberg C, Rumjanek VM, Monteiro RQ. Assembly and regulation of prothrombinase complex in B16F10 melanoma cells. Thromb Res 2005; 115: 123-9.
29. Ieko M, Tarumi T, Takeda M, Naito S, Nakabayashi T, Koike T. Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in haemostasis. J Thromb Haemost 2004; 2: 612-8.
30. Mousa SA, Mohamed S. Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: Anti-cancer efficacy. Oncol Rep 2004; 12: 683-8.
31. Chi L, Rogers KL, Uprichard AC, Gallagher KP. The therapeutic potential of novel anticoagulants. Expert Opin Investig Drugs 1997; 6: 1591-605.
32. Leadley Jr RJ, Chi L, Porcari AR. Non-hemostatic activity of coagulation factor Xa: Potential implications in various diseases. Curr Opin Pharmacol 2001; 1: 169-75.
33. Walenga JM, Jeske WP, Hoppensteadt D, Fareed J. Factor Xa inhibitors. Methods Mol Med 2004; 93: 95 -117.
34. Brueggemann LW, Reitsma PH, Spek CA. Anticoagulants inhibit tumor metastasis independent of fibrin formation. Hematologica Reports 2005; 1: 112-113.